Immunogenicity of Oxford-AstraZeneca COVID-19 Vaccine in Vietnamese Health-Care Workers
This article has been Reviewed by the following groups
Listed in
- Evaluated articles (ScreenIT)
Abstract
We studied the immunogenicity of the Oxford-AstraZeneca vaccine in health-care workers of a major infectious diseases hospital in Vietnam. We measured neutralizing antibodies before and 14 days after each dose, and at day 28 and month 3 after dose 1. A total of 554 workers (136 men and 418 women; age range, 22–71 years; median age, 36 years) participated with the study. Of the 144 participants selected for follow-up after dose 1, 104 and 94 gave blood for antibody measurement at weeks 6 and 8, and at month 3 after dose 1, respectively. The window time between the two doses was 6 weeks. At baseline, none had detectable neutralizing antibodies. After dose 1, the proportion of participants with detectable neutralizing antibodies increased from 27.3% (151 of 554) at day 14 to 78.0% (432 of 554) at day 28. Age correlated negatively with the development and the levels of neutralizing antibodies. However, at day 28, these differences were less profound, and women had a greater seroconversion rate and greater levels of neutralizing antibodies than men. After dose 2, these age and gender associations were not observable. In addition, the proportion of study participants with detectable neutralizing antibodies increased from 70.2% (73 of 104) before dose 2 (week 6, after dose 1) to 98.1% (102 of 104) 14 days later. At month 3, neutralizing antibodies decreased and 94.7% (89 of 94) of the study participants remained seropositive. The Oxford-AstraZeneca COVID-19 vaccine is immunogenic in Vietnamese health-care workers. These data are critical to informing the deployment of the COVID-19 vaccine in Vietnam and in Southeast Asia, where vaccination coverage remains inadequate.
Article activity feed
-
-
-
SciScore for 10.1101/2021.07.08.21260162: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
Ethics IRB: Ethics: The study was approved by the Institutional Review Board of HTD and the Oxford Tropical Research Ethics Committee, University of Oxford, UK.
Consent: Written informed consents were obtained all the participants.Sex as a biological variable not detected. Randomization After day 28 of the first dose, blood sampling was narrowed down to a subgroup of 144 individuals randomly selected from the study participants for subsequent follow up. Blinding not detected. Power Analysis not detected. Table 2: Resources
Software and Algorithms Sentences Resources The analyses were carried using Prism 9.0.2 (graphpad.com). Prismsuggested: (PRISM, RRID:SCR_005375)Results from OddPub: We did not detect open …
SciScore for 10.1101/2021.07.08.21260162: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
Ethics IRB: Ethics: The study was approved by the Institutional Review Board of HTD and the Oxford Tropical Research Ethics Committee, University of Oxford, UK.
Consent: Written informed consents were obtained all the participants.Sex as a biological variable not detected. Randomization After day 28 of the first dose, blood sampling was narrowed down to a subgroup of 144 individuals randomly selected from the study participants for subsequent follow up. Blinding not detected. Power Analysis not detected. Table 2: Resources
Software and Algorithms Sentences Resources The analyses were carried using Prism 9.0.2 (graphpad.com). Prismsuggested: (PRISM, RRID:SCR_005375)Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).
Results from LimitationRecognizer: We detected the following sentences addressing limitations in the study:Our study has some limitations. We did not study cellular immunity, especially T cell response. And due to the age and gender structure in nature of HTD staff, we did not include participants older than 71 years and females were predominant among our study subjects. Compared with males, females seemed to better respond to Oxford-AstraZeneca COVID-19 vaccine at day 28 after the first dose, which warrants further research.
Results from TrialIdentifier: No clinical trial numbers were referenced.
Results from Barzooka: We did not find any issues relating to the usage of bar graphs.
Results from JetFighter: We did not find any issues relating to colormaps.
Results from rtransparent:- Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
- Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
- No protocol registration statement was detected.
Results from scite Reference Check: We found no unreliable references.
-